Group 1 - Mingyuan Investment recently conducted research on a listed company, Haichuang Pharmaceutical, which has received approval for its core product, Deutetrabenazine soft capsules, a first-class new drug for treating mCRPC, significantly extending patients' progression-free survival [1] - The clinical trial for HP515, aimed at treating MSH, is currently ongoing in China, with preliminary data indicating good safety of the drug [1] - The company is also conducting a Phase II clinical trial for HP518, which has received fast track designation in the United States [1] - Haichuang Pharmaceutical has established a four-wheel drive commercialization strategy, combining self-built teams with external collaborations to comprehensively advance product commercialization preparations [1] Group 2 - Mingyuan Investment Management Co., Ltd. was established in 2014 in Shanghai, with a registered capital of 10 million yuan, founded by Dr. Qiu Huiming, who has extensive experience in hedge funds on Wall Street [2] - The company has obtained the private securities investment fund manager qualification and observation member qualification approved by the Asset Management Association of China [2] - Mingyuan Investment focuses on quantitative investment, leveraging strong data mining, statistical analysis, and software development capabilities to build a systematic trading and asset management platform [2] - The investment scope includes stocks, futures (index and commodity futures), and options, with a diverse strategy development team and a robust strategy library [2] - The company aims to explore and research quantitative investment strategies suitable for the characteristics of the Chinese capital market, integrating global leading financial institutions' experiences and technologies [2]
【私募调研记录】明汯投资调研海创药业